Well Referenced

Tag: mTOR inhibitor

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

This retrospective study assessed the safety and efficacy of sirolimus, an mTOR inhibitor, combined with endocrine therapy in 36 patients with advanced hormone receptor-positive (HR+) breast cancer. The combination yielded a median progression-free survival (PFS) of 4.9 months and an objective response rate of 19.4%, with a clinical benefit rate

Read More »
June 26, 2025 No Comments

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

This phase I, nonrandomized, open-label study evaluated the safety and efficacy of combining the histone deacetylase inhibitor vorinostat with either the mTOR inhibitor sirolimus (V+S) or everolimus (V+E) in 40 patients with relapsed/refractory Hodgkin lymphoma who had undergone a median of five prior therapies, including brentuximab and stem cell transplantation.

Read More »
June 26, 2025 No Comments